35 results about "Coliphage" patented technology

The invention belongs to the field of poultry infectious diseases, and particularly relates to a riemerella anatipestifer phage mutant strain and a method for quickly mutating riemerella anatipestifer phage. Escherichia coli bacteriophage, riemerella anatipestifer bacteriophage and corresponding host bacteria are mixed, the infection complex number is made to be larger than 100, after culture, supernate is taken and then mixed with the host bacteria for culture, a bacteriophage mutant strain is separated from a secondary culture solution, the phage spectrum of the bacteriophage mutant strain is detected, and the mutant strain with the broadened phage spectrum is screened. At present, no report for widening the bacteriophage spectrum of the riemerella anatipestifer based on similar principles is found, and the research can fill the blank in the related research field.

The invention relates to a diarrhea-related multi-drug-resistant coliphage and application thereof. In particular to a bacteriophage vBEcoMP66 screened from a multi-drug-resistant escherichia coli library, and the bacteriophage vBEcoMP66 is preserved in the China Center for Type Culture Collection on December 12, 2024, and the preservation number is CCTCC M 20242794. The bacillus subtilis has a splitting effect on multiple strains of multi-drug-resistant escherichia coli and piglet diarrhea pathogenic escherichia coli strains, and also has an obvious inhibition effect on bacteria in a biological membrane, and the inhibition capability is superior to the antibiotic level under the same condition. Besides, the bacteriophage has extremely low host resistance mutation frequency, the resistance mutation frequency of host bacteria can be effectively reduced, animal experiments show that the bacteriophage has the effects of preventing piglet diarrhea and reducing the level of inflammatory factors in vivo, and the bacteriophage has extremely high industrial value and wide application prospects.

The invention provides a quality control kit of a nucleic acid detection system as well as a quality control method and application of the quality control kit. The quality control kit comprises the coliphage MS2 and a first sequence group. The first sequence group comprises a forward primer of a sequence as shown in SEQ IQ NO: 1, a reverse primer of a sequence as shown in SEQ IQ NO: 2 and a probe of a sequence as shown in SEQ IQ NO: 3. The quality control method comprises the following steps: mixing a specimen with bacteriophage MS2, and carrying out nucleic acid extraction to obtain an eluent; and mixing an eluent with the feline blood plasma bacterial plastid, the first sequence group and the second sequence group, and carrying out multiple real-time polymerase chain reaction. The quality control kit of the nucleic acid detection system is used for evaluating the recovery rate of nucleic acid and the whole-process quality control of the nucleic acid detection system.

The invention belongs to the technical field of microorganisms, and discloses a phage capable of efficiently splitting escherichia coli and salmonella, a preparation and application of the phage, the name is SP1, the classification name is escherichia coli phage, the preservation number is CGMCC No.46440, the preservation date is China General Microbiological Culture Collection Center on May 30, 2025, and the preservation unit is China General Microbiological Culture Collection Center. The optimal infection complex number of the bacteriophage is 1, the bacteriophage has very strong acid resistance and thermal stability, and the bacteriophage can keep high titer under the conditions that the pH value is 4-11, the temperature is 10-70 DEG C and the ultraviolet irradiation is within 30 minutes. The incubation period of escherichia coli infected by the bacteriophage is about 30 min, the outbreak period is about 40 min after the incubation period, and the bacteriophage can specifically split escherichia coli and salmonella, does not contain virulence and drug-resistant genes and is high in biological safety.

The invention provides a cross-species lysis bacteriophage RDP-EC-20146 and application thereof, and belongs to the technical field of biology. The cross-species lysis bacteriophage is an escherichia coli bacteriophage, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.45351, and the cross-species lysis bacteriophage is preserved in China General Microbiological Culture Collection Center on October 28, 2022. The cross-species lysis bacteriophage RDP-EC-20146 provided by the invention has the characteristics of high lysis activity and good physical and chemical factor tolerance; the method is not influenced by the drug resistance of bacteria, does not have the problems of drug residues and the like, and has very high use safety; in addition, when the bacteriophage RDP-EC-20146 provided by the invention is combined with 8 low-dose antibiotics for use, a remarkable bacteriostatic effect can be shown, and the bacteriophage RDP-EC-20146 has a good application prospect in the aspect of preventing and treating salmonella, escherichia coli, staphylococcus aureus and / or pseudomonas aeruginosa diseases.

The invention relates to the technical field of microorganisms, in particular to an escherichia coli bacteriophage for improving the antibacterial effect of cecropin and application of the escherichia coli bacteriophage. The bacteriophage is named as RDP-EC-22139, the genome of the bacteriophage does not contain virulence genes and lyogenicity related genes, and the bacteriophage has good biological safety. The bacteriophage has relatively strong lysis activity on drug-resistant pathogenic escherichia coli, can still keep stable lysis titer in a relatively wide temperature and pH condition range, and has good genetic stability. When the bacteriophage is combined with cecropin for use, the minimum inhibitory concentration of the cecropin on drug-resistant pathogenic escherichia coli is remarkably reduced, the minimum inhibitory concentration can be reduced to 1 / 2-1 / 8 of the minimum inhibitory concentration when the cecropin is independently used, the inhibition time on pathogenic bacteria is remarkably prolonged, and a stable and unexpected synergistic antibacterial effect is shown. The invention provides a safe and effective biological technical scheme for prevention and control of drug-resistant Escherichia coli infection, and has a good application prospect.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The invention discloses an Escherichia coli bacteriophage D9, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D9 is CGMCC (China General Microbiological Culture Collection Center) NO. 46365, and the Escherichia coli bacteriophage D9 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D9 and other bacteriophages. The coliphage D9 has better high-temperature resistance and acid resistance, is high in breeding speed, is suitable for industrial production, has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a pharmaceutical preparation or a disinfectant, and has a wide application prospect. The compound is applied to the aspects of sterilization, bacteriostasis and disinfection of multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by escherichia coli and the like.

The invention relates to an engineered bacteriophage targeting drug-resistant gram-negative bacteria, a screening method and application. The engineered phage is Escherichia phage M13, the preservation time is February 11, 2025, the preservation address is China Center for Type Culture Collection (CCTCC), Wuhan University, Wuchang District, Wuhan City, Hubei Province, and the preservation number is CCTCC No: M 2025196. The invention also provides application of the engineered bacteriophage in preparation of medicines for treating and diagnosing multi-drug-resistant gram-negative bacterium infection. The invention also provides a kit for diagnosing or treating multi-drug-resistant gram-negative bacterium infection, and the kit comprises the bacteriophage. The invention also provides a screening method of the engineered bacteriophage. The invention solves the problem that the natural bacteriophage is targeted to single species of bacteria and is difficult to cope with common mixed infection of multiple drug-resistant bacteria clinically.

The invention discloses an escherichia coli bacteriophage E2P and application thereof, and belongs to the technical field of microorganisms. The preservation number of the coliphage E2P is CCTCC (China Center For Type Culture Collection) NO: M 20241067, and the preservation time of the coliphage E2P is May 27, 2024. The coliphage E2P is used for preventing and treating Escherichia coli infection of poultry, is wide in host spectrum, high in splitting activity, large in temperature and acid-base tolerance range, high in titer and short in fermentation time, can be used as a feed additive or medicine, can reduce the feed conversion ratio and improve the survival rate, and is wide in application prospect.

The invention discloses an Escherichia coli bacteriophage D5, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D5 is CGMCC (China General Microbiological Culture Collection Center) NO. 46364, and the Escherichia coli bacteriophage D5 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D5 and other bacteriophages. The Escherichia coli phage D5 has good high temperature resistance and acid resistance, the environmental tolerance enables the Escherichia coli phage D5 to keep high activity and stability and high breeding speed in industrial production, and the Escherichia coli phage D5 is suitable for industrial production and supports rapid proliferation and large-scale fermentation production requirements; the compound has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a medicinal preparation or a disinfectant, and is applied to the aspects of sterilization, bacteriostasis and disinfection of the multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by the escherichia coli and the like.

The invention relates to a strain of virulent Escherichia coli bacteriophage PYYF4 and a culture method thereof, a bacteriophage composition, a feed additive, a sterilization and disinfection preparation and application, and belongs to the technical field of microorganisms. The virulent escherichia coli bacteriophage PYYF4 disclosed by the invention can be used for effectively preventing and / or treating infection caused by pathogenic escherichia coli and can be used for disinfecting environments and instruments. Moreover, the strong escherichia coli bacteriophage PYYF4 disclosed by the invention has a high splitting rate and a broad-spectrum bactericidal effect, keeps stable in the pH range of 4-11 and the temperature range of 40-60 DEG C, and shows good environmental adaptability. Meanwhile, the virulent escherichia coli bacteriophage PYYF4 is free of toxic and side effects, high in safety, easy to prepare into spraying liquid, convenient for practical application and wide in application prospect in the aspects of escherichia coli infection prevention and treatment, environment disinfection and animal disease treatment.

The application discloses an Aeromonas phage recombinant system, an expression vector, a recombinant strain and application thereof, and the recombinant system comprises a recombinase operon 109TES derived from a salmonella Aeromonas phage vB_AsaM-56; the operon comprises at least one gene with exonuclease function and one single-stranded DNA annealing protein gene. Through function verification in Escherichia coli, 109TES can efficiently mediate linear circle recombination and linear linear recombination by using a short homologous arm (50 bp), and has stable and reliable recombination function in a heterologous host, indicating that the recombinase operon from a non-Escherichia coli phage can also exert efficient homologous recombination function in Escherichia coli, and can be used as a powerful candidate for constructing a new type of recombination tool, and provides a new choice for developing a multi-host available gene editing system.

The invention discloses an escherichia coli phage P-GXEC-L2P5 strain capable of producing shiga toxin, which is an escherichia coli phage P-GXEC-L2P5, and the preservation number of the escherichia coli phage P-GXEC-L2P5 capable of producing shiga toxin is CCTCC (China Center for Type Culture Collection) M 2025071. The shiga toxin-producing escherichia coli bacteriophage P-GXEC-L2P5 can split 18 wide-spectrum escherichia coli bacteriophages of escherichia coli from different sources, can kill various bacteria at the same time, is high in stability and good in safety, can be easily prepared into preparations and the like, and has good treatment and killing effects on animals infected with escherichia coli and environments polluted by escherichia coli.

The invention relates to the technical field of preparation of biological agents, and particularly discloses a method for improving the stability and antibacterial persistence of an Escherichia coli bacteriophage preparation. The method comprises the following steps: adding chitosan in a culture process of escherichia coli host bacteria, and inoculating bacteriophage to complete lysis proliferation when the host bacteria are in a logarithmic phase; sequentially carrying out low-shear-force centrifugation, membrane filtration and membrane concentration treatment on the obtained bacteriophage proliferation liquid; adding a compound stabilizer consisting of EDTA (Ethylene Diamine Tetraacetic Acid), glycine, glycerol, trehalose and polyethylene glycol into the concentrated bacteriophage solution for stabilizing treatment; and finally, carrying out multi-stage filtration sterilization to obtain the phage preparation. The coliphage preparation prepared by the method shows good titer retention performance under normal-temperature and low-temperature storage conditions, and has longer effective antibacterial duration. The method is mild in preparation process, high in repeatability and suitable for large-scale preparation.

The purpose is to provide a novel bacteriophage having a wider range of bacterial strains that serve as hosts for infection than conventional bacteriophages and having bacteriolytic activity against Escherichia coli, including drug-resistant E. coli. The present inventors have discovered a novel bacteriophage having a broad antibacterial spectrum against E. coli, including drug-resistant E. coli. The phage was named ΦWec 277 phage and deposited with the Patent Microorganism Depositary (NPMD) of the National Institute of Technology and Evaluation (NITE) (accession number: NITE P-04067). It was discovered that E. coli can be effectively eliminated by using this bacteriophage, and the present invention was completed. Furthermore, genomic analysis of the ΦWec 277 phage was performed to clarify the full-length sequence. This ΦWec 277 phage was identified as a bacteriophage belonging to the Caudoviricetes Straboviridae as a result of phylogenetic analysis.

The invention relates to the technical field of biology, in particular to phage receptor binding protein D911 and application thereof. The invention provides preparation of an Escherichia coli phage receptor binding protein D911 and application of the Escherichia coli phage receptor binding protein D911 in detection of escherichia coli. The bacteriophage receptor binding protein D911 can specifically recognize and bind escherichia coli, the protein is further coupled with magnetic nanoparticles to form an escherichia coli receptor binding protein-magnetic bead conjugate D911-MNP, and a biological probe for specifically recognizing and binding escherichia coli is prepared and serves as an escherichia coli specific capture reagent. And a constructed escherichia coli separation and detection method. The method has the advantages of rapidness, convenience, specificity, sensitivity and accuracy, is expected to be applied to rapid detection of escherichia coli, and provides powerful technical support for escherichia coli detection in the fields of clinical diagnosis, food safety, environment and the like.

The present invention relates to an efficient Escherichia coli phage and its application. The phage is named LYE-01, and its taxonomic name is Escherichia coliphage. The preservation number is CGMCC No. 46095, the preservation date is August 7, 2024, and the preservation institution is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms. The present invention provides a phage LYE-01 of Escherichia coli. The optimal multiplicity of infection of this phage is 1. It has strong acid resistance and thermal stability. Under the conditions of pH value 4-11, temperature 10°C-50°C, and ultraviolet irradiation within 20 minutes, this phage can maintain a high titer. The one-step growth curve experiment shows that the latent period of this phage infecting Escherichia coli is about 10 minutes, the burst period is about 40 minutes thereafter, and the stable plateau period is after 50 minutes of phage infection.

The invention discloses an aeromonas bacteriophage recombination system, an expression vector, a recombination strain and application of the aeromonas bacteriophage recombination system. The recombination system comprises a recombinase operon 109TES derived from aeromonas salmonicida bacteriophage vBAsaM-56; the operon comprises at least one gene with exonuclease function and a single-stranded DNA annealing protein gene. Through functional verification in Escherichia coli, 109TES can utilize a short homologous arm (50bp) to efficiently mediate wire loop recombination and wire-line recombination, and has a stable and dependable recombination function in a heterologous host, which indicates that a recombinase operon from a non-Escherichia coli bacteriophage can also exert an efficient homologous recombination function in the Escherichia coli, so that the recombinant enzyme operon can be used for preparing a recombinant vector. The method can be used as a powerful candidate for constructing a novel recombination tool, and a new choice is provided for developing a multi-host available gene editing system.

The present application relates to a pathogen-like antigen (PLA) complex, and a preparation method therefor and an application thereof. The PLA complex consists of structurally-modified Escherichia coli bacteriophage virus-like particles (VLPs) and antigens displayed thereon, and nucleic acids are encapsulated inside the VLPs.

The invention discloses an escherichia coli bacteriophage GXEC2-19, which is an escherichia coli bacteriophage GXEC2-19, the preservation number of the escherichia coli bacteriophage GXEC2-19 is CCTCC (China Center for Type Culture Collection) NO: M 20242555, and the preservation number of the escherichia coli bacteriophage GXEC2-19 is CCTCC NO: M 20242555. The invention also discloses an application of the coliphage GXEC2-19 in preparation of drugs for preventing and treating avian pathogenic coliphage infection diseases. The escherichia coli phage GXEC2-19 Escherichia phage GXEC2-19 disclosed by the invention can be used for effectively cracking chicken-origin pathogenic escherichia coli, wherein the chicken-origin pathogenic escherichia coli comprises escherichia coli phage DC05 and another strain of chicken-origin escherichia coli; furthermore, the coliphage GXEC2-19 can continuously inhibit bacteria for a long time, is high in stability and good in safety, can be easily prepared into preparations and the like, and has good killing, preventing and controlling effects on environments, feeds and the like polluted by the coliphage.

The application belongs to the technical field of biotechnology, and discloses a traditional Chinese medicine compound preparation containing an Escherichia coli bacteriophage DCP514 and application. The Escherichia coli bacteriophage DCP514 has a preservation number of CCTCC NO: M 2024321, can efficiently kill pathogenic variants of Escherichia coli in a poultry breeding environment, has the characteristics of strong lyticity, good temperature tolerance, environmental friendliness, and the like, and has the advantages of safety, no residue, and no side effect. The bacteriophage can be used alone or in combination with a traditional Chinese medicine extract to enhance the bacteriostatic effect, and has a good application prospect in the biological control of Escherichia coli.

Provided are a phage and a use thereof in preparing a biological formulation for inhibiting drug-resistant bacteria, relating to the field of biomedicine. An Escherichia coli phage Phage vB_EcoM_GZMU_E1004 is isolated from a mixture of lake water and sewage. The phage is deposited under the accession number GDMCC No: 64729-B1, and has the function of significantly inhibiting Escherichia coli. In addition, the combined use of the phage and allicin can further enhance the antibacterial effect against Escherichia coli. The obtained phage can reduce the use of antibiotics, enrich the natural phage resources of drug-resistant Escherichia coli, and provide an important foundation and basis for the phage treatment of drug-resistant Escherichia coli.

The invention provides a bovine-derived Escherichia coli bacteriophage, which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 2025205. The bovine-derived escherichia coli bacteriophage can survive in an environment with the pH value of 3.0-12.0, has good titer stability at the temperature of 4-50 DEG C, has good pH and temperature tolerance, and is suitable for preparing drugs and disinfectants for inhibiting bovine-derived escherichia coli.

The invention discloses a drug-resistant Escherichia coli bacteriophage with efficient cross-species lysis capability and application of the drug-resistant Escherichia coli bacteriophage, the drug-resistant Escherichia coli bacteriophage is named as Escherichia coli bacteriophage PE-48, and the preservation number of the drug-resistant Escherichia coli bacteriophage is CCTCC (China Center for Type Culture Collection) NO: M 2025261. The strain not only can efficiently split pathogenic escherichia coli, but also can split salmonella, has efficient cross-species splitting capacity, and can effectively prevent and treat various symptoms caused by escherichia coli and relieve phenomena such as large-scale death and the like. The bacteriophage is separated from the natural environment, is a natural biological purification factor, and has the advantages of being green, environmentally friendly, safe, free of residues, efficient in bacteriostasis and the like. Escherichia coli and salmonella infection can be effectively prevented and treated in the chick breeding process.

A biosensor tool that uses a novel phage Qβ display technology to monitor the presence of the biological or chemical threat. The biosensor including a probe specific to the biological or chemical threat and a detectable molecule expressed on the surface of the phage Qβ and an analyte capable of binding to the probe and blocking the detectable molecule.

The application provides a cross-species lytic bacteriophage RDP-EC-20146 and an application thereof, and belongs to the technical field of biotechnology. The cross-species lytic bacteriophage is an Escherichia coli bacteriophage, the preservation number of which is CGMCC No. 45351, and the bacteriophage is preserved in the China General Microbiological Culture Collection Center on October 28, 2022. The cross-species lytic bacteriophage RDP-EC-20146 provided by the application has high lytic activity and good physical and chemical factor tolerance characteristics; the cross-species lytic bacteriophage is not affected by bacterial drug resistance, and does not have problems such as drug residues, and has high use safety; in addition, the bacteriophage RDP-EC-20146 provided by the application can all show significant bacteriostatic effects when being used in combination with low-dose 8 kinds of antibiotics, and has a good application prospect in the prevention and treatment of salmonellosis, colibacillosis, staphylococcosis and / or pseudomonas aeruginosa disease.

This invention proposes an *Escherichia coli* bacteriophage, a bacteriophage composition, its application, and a bacteriophage preparation, relating to the field of microbial technology. The *Escherichia coli* bacteriophage is named *Escherichia coli* bacteriophage GaoM7-14E, with accession number CGMCC NO.46188, deposited on September 20, 2024. Another *Escherichia coli* bacteriophage is named *Escherichia coli* bacteriophage JM3e, with accession number CGMCC NO.46186, deposited on September 18, 2024. The technical solution of this invention uses bacteriophage GaoM7-14E and bacteriophage JM3e as a bacteriophage composition, which can synergistically inhibit *Escherichia coli*, thereby inhibiting pathogenic *Escherichia coli*, and thus preventing and treating *Escherichia coli* diseases.

The invention discloses expression and application of an Escherichia coli phage and endolysin thereof, and belongs to the technical field of microorganisms, the Escherichia coli phage VB-EcoM-WM is separated from diarrhea cattle manure of a certain cattle farm in Sichuan, the Escherichia coli phage VB-EcoM-WM is preserved in China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 2025810, the endolysin of the Escherichia coli phage VB-EcoM-WM has broad-spectrum lysing property on bacteria, and the endolysin of the Escherichia coli phage VB-EcoM-WM has broad-spectrum lysing property on bacteria. The endolysin is subjected to hydrophobic modification and prokaryotic expression to obtain the fused endolysin protein, so that the cleavage property of the endolysin is more broad-spectrum and efficient. The gene engineering modified fusion protein not only can crack host escherichia coli, but also has a bacteriostatic effect on 15 tested bacteria such as salmonella, streptococcus, staphylococcus and pasteurella. The minimum inhibitory concentration on escherichia coli is 0.1 mu g / ml. The traditional antibiotics can be replaced.

The invention belongs to the technical field of bacteriophages, and discloses an Escherichia coli bacteriophage PD2061, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage PD2061 is CGMCC NO.46163, the Escherichia coli bacteriophage PD2061 is preserved in China General Microbiological Culture Collection Center on August 16, 2024, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The Escherichia coli phage PD2061 not only has a high splitting rate on Escherichia coli, but also has certain splitting performance on salmonella, and has greater advantages in prevention and treatment of diseases caused by mixed infection of Escherichia coli and salmonella. The bacteriophage can be used for preparing a medicinal preparation for treating or preventing animal-derived colibacillosis and / or salmonellosis, the survival rate of poultry suffering from colibacillosis / salmonellosis or mixed infection diseases is increased, the feed utilization rate is increased, and the death and culling rate of the poultry in breeding is reduced.